Navigation Links
Targeted radiation therapy minimizes GI side effects for prostate cancer patients, Penn study shows
Date:10/26/2010

SAN DIEGO -- Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine. The study, which will be presented Nov. 1 at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego, found that men who were treated with IMRT had fewer serious bowel complications, including painful rectal inflammation and bleeding (3.5 percent), compared to those who received CRT (4.5 percent).

"While radiotherapy is highly effective in treating prostate cancer, men may live with gastrointestinal, urinary and sexual side effects of treatment for many years. Minimizing these side effects and improving men's quality of life after prostate cancer treatment is incredibly important," says Justin Bekelman, MD, lead author of the study and an assistant professor of Radiation Oncology at the University of Pennsylvania School of Medicine. "Our study offers important evidence to patients and their doctors that IMRT is associated with fewer gastrointestinal problems after treatment."

CRT, the conventional form of radiation therapy, uses imaging studies including CT, MRI and PET scans to map the size, shape and location of tumors and the other organs in the area. IMRT is a more advanced version of CRT, offering a more targeted dose of radiation to the cancerous prostate gland. Since both forms of radiation pass all the way through the body after attacking their target, healthy tissue in the rectum and bladder may be damaged by the radiation beam, causing side effects during and after treatment. Though Medicare and private insurers typically cover both IMRT and CRT, little research has been conducted to show which treatment is associated with less side effects an important consideration for men choosing among the various treatment options for the disease, which include observation, radiation, surgery, chemotherapy and hormonal therapies.

Using a Medicare database of men across the United States, Bekelman's team studied 12,598 men 65 years and older who were diagnosed with non-metastatic prostate cancer between 2002 and 2004. The authors followed the patients through 2006 and identified complications that were serious enough to require invasive procedures (including surgeries) and/or hospitalization. The findings revealed that among men who received IMRT, 18.8 percent had serious bowel complications during the two years after their treatment, compared to 22.5 percent of men treated with CRT. (Since specifics about each patient's case could not be accounted for in the database, the authors note that some of the complications identified may have been caused by factors other than radiation treatment.) The researchers found no substantial difference in incidence of urinary or sexual side effects such as erectile dysfunction, but Bekelman notes that since the study was limited to complications involving invasive surgical procedures, it may not capture the true prevalence of sexual side effects following treatment, for which patients may have sought less invasive remedies.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Targeted delivery of losartan reduces liver inflammation and scarring
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
4. Targeted agent blocked growth of deadly brain cancer in preclinical studies
5. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
6. New targeted therapy effective in treating advanced prostate cancer
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Women Smokers Targeted on World No Tobacco Day
11. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: